Latest news with #Diabetes
The Standard
14 hours ago
- Health
- The Standard
Survey: Nearly 60% of Respondents Reported Experiencing Abnormalities in Drinking Water Quality
(Right) Dr. TONG Chun Yip, Peter, Specialist in Endocrinology, Diabetes & Metabolism; A patient who concern the quality of water, Ha
Daily Tribune
3 days ago
- Health
- Daily Tribune
First aid workshop for children with diabetes
As part of the activities of the Summer Program for Children with Diabetes, the Bahrain Red Crescent Society (BRCS) organized an educational training workshop on basic first aid for children, as part of the ongoing cooperation and coordination with the Bahrain Diabetes Society. The workshop was prepared and implemented by Ms. Fatima Abdulrahman, Head of the First Aid Committee at the Society, in cooperation with a distinguished team of BRCS trainers, including Mr. Mohammed Ashour, Mrs. Afaf Bujeri, and Mr. Jamal Salem, accompanied by Dr. Fatima Mohammed, which enriched the training content and provided an integrated educational experience for the participating children. The workshop was also attended and supervised by Dr. Maryam Al Hajri, Member of BRCS board, who stressed the importance of continuing such awareness initiatives and joint programs that serve different segments of society, especially children with chronic diseases, and contribute to building a more aware generation capable of taking care of their health.
Yahoo
5 days ago
- Health
- Yahoo
Continuous glucose monitors are in vogue. But do you really need to track your blood sugar?
A quarter-size device that tracks the rise and fall of sugar in your blood is the latest source of hope — and hype — in the growing buzz around wearable health technology. Continuous glucose monitors, small patches that provide 24-hour insight into concentrations of sugar in the blood, could be a tool for Americans to 'take control over their own health,' Health Secretary Robert F. Kennedy Jr. recently told federal lawmakers. 'They can take responsibility,' Kennedy said. 'They can begin to make good judgments about their diet, about their physical activity, about the way they live their lives.' The devices have lifesaving benefits for people with diabetes, the disease caused when blood sugar remains high because their bodies don't make enough insulin or become resistant to it. The condition, which affects more than 38 million people in the U.S., raises the risk of serious health problems such as heart and kidney disease and vision loss. But the devices have surged in popularity among people without diabetes. Sales have been driven by high-profile marketers such as Casey Means, the nominee for U.S. surgeon general. There's scant evidence the monitors are useful for people with normal blood sugar levels, said Dr. Jody Dushay, an endocrine specialist at Beth Israel Deaconess Medical Center. Healthy bodies can effectively regulate glucose after meals and provide the energy they need to function. Glucose monitors may lead people to misinterpret normal swings in blood sugar that happen after eating or activity. In addition, the devices can be 'notoriously inaccurate,' providing misleading readings, she said. 'The problem with wearing these is that you can just be zooming in on and creating pathology when it's not there,' Dushay said. Here's what you need to know about the devices: Here's what a continuous glucose monitor does The device is a small patch, about the size of two stacked quarters, usually placed on the upper arm or stomach. It uses a needle to painlessly pierce the skin for a tiny sensor. The sensor measures the glucose in fluid under the skin, delivering a signal every few minutes to a phone app or a handheld display. The apps typically record blood sugar levels and help people track the foods they eat and how they impact those levels. When healthy people eat a meal that contains carbohydrates, their blood sugar rises, peaks and falls in response to the food. A healthy fasting blood glucose level for a person without diabetes is roughly 70 milligrams per deciliter to 99 milligrams per deciliter. A range from 100 to 126 milligrams per deciliter indicates prediabetes and above 126 milligrams per deciliter indicates diabetes, according to the American Diabetes Association. In adults without diabetes, blood sugar levels can climb to 140 milligrams per deciliter or more within an hour of a meal, before falling back to baseline levels within two or three hours, according to the association. It's a sign the body is processing sugar normally. Continuous glucose monitors have been available since the late 1990s For decades, these devices were available only for people with diabetes. The monitors revolutionized care by allowing more precise adjustment of insulin used to treat diabetes and giving people the ability to modify meals and activity more accurately. Last year, the U.S. Food and Drug Administration approved the first over-the-counter monitors. Since then, many companies have emerged to market them, claiming to provide intensive, individualized health monitoring. Cost is generally about $100 a month. They've really caught on with consumers curious about how food and activity affect their blood sugar levels. For instance, Noom, the weight-loss and fitness app, launched a blood glucose feature last year that has proven extremely popular, said Alexander Fabry, a company executive. 'Of the people who are using a CGM, the vast majority of them don't have a diabetes diagnosis,' he said. Who can use the monitors? The devices have been lifesaving for people with diabetes. And they can be helpful for people with risk factors for the disease, including obesity, prediabetes, a history of gestational diabetes or a family history of the condition. The devices can allow users to see how specific food and activity choices affect their blood sugar in near real-time, said Dr. Alaina Vidmar, a pediatric obesity specialist at Children's Hospital Los Angeles. 'After a large meal, you may watch your blood sugar go up and sort of learn something about yourself,' Vidmar said. 'For example, I drink a sugar-sweetened soda and my blood sugar goes up really high, really fast. And maybe I don't feel as good, right?' What are the cautions? People without risk factors for diabetes may turn to the monitors just because they're curious, said Dr. David Kessler. A former FDA commissioner, Kessler doesn't have diabetes, but he wore a monitor for a couple months during research for his recent book, 'Diet, Drugs and Dopamine.' 'I think it's a very interesting tool to experiment with if you're so inclined,' Kessler said. But, he noted, the devices can't be used to diagnose or treat disease. Even experts don't agree on how to interpret or provide health advice for people without diabetes based on blood sugar data. 'No one knows what's optimal in the nondiabetic state,' he said. Before using a monitor, Dushay asks patients to consider their motives. 'What do you think you're going to get from the data?' she said. 'What is to be gained from wearing that monitor?' ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. Jonel Aleccia, The Associated Press Sign in to access your portfolio
Yahoo
24-07-2025
- Health
- Yahoo
Ascensia Launches Global Art Competition Exploring the Link Between Diabetes and Anxiety
Fourth annual initiative supports World Diabetes Day 2025 with patient-led creativity and storytelling BASEL, Switzerland, July 24, 2025--(BUSINESS WIRE)--Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, has launched its fourth annual global art competition in support of World Diabetes Day 2025. This year, the competition is themed around Diabetes and Anxiety, shining a spotlight on the mental health impact of diabetes and capturing the unfiltered reality of living with the condition. An estimated 3 in 4 people living with diabetes have experienced anxiety, depression or another mental health condition as a result of managing their diabetesi. With the number of people affected by diabetes expected to rise to over 850 million by 2050ii, this year's This is Diabetes. This is Anxiety. campaign aims to raise awareness and deepen understanding through creativity and storytelling. Submissions are now open globally and free to enter at until October 24, 2025, with the winners announced on World Diabetes Day, a global initiative of the International Diabetes Federation (IDF), held each year on November 14. Koichiro Sato, CEO of Ascensia Diabetes Care and Chief Operating Officer and Chief Strategy Officer of Ascensia's parent company PHC Group, commented: "World Diabetes Day is a key moment for us to support the global diabetes community. For 2025, we want to shed light on the emotional burden that often goes unseen. The theme of 'This is Diabetes. This is Anxiety.' is deeply important, and we hope this competition provides an outlet for expression, connection and better quality of life." "Each year we are inspired by the stories shared through art," he continued. "We invite artists, supporters, and advocates to help us show the world what anxiety and diabetes truly look like. Every submission adds to a collective story that deserves to be seen and heard." In addition to showcasing the Top 20 submissions across Ascensia's platforms, the 2025 competition will introduce a free downloadable coloring-in booklet featuring selected artwork. This new initiative is designed to spark creativity, reflection and learning for individuals and families alike. Prizes include donations of €6,000, €3,000 and €1,000 made in the winners' names to a diabetes charity of their choice. A diverse judging panel – including global artists, diabetes advocates, and Ascensia employees – will evaluate submissions based on creativity, emotional impact, connection to the theme, and storytelling. Now in its fourth year, the competition builds on the momentum of previous This is Diabetes campaigns, which have drawn over 500 entries and delivered donations to diabetes charities on four continents. Ascensia Diabetes Care is a PHC Holdings Corporation (TSE: 6523) company. Terms and conditions apply. Notes for Editors About Ascensia Diabetes Care Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives. We are home to the world-renowned CONTOUR® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity. Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 100 countries. Ascensia has around 1,400 employees and operations in 29 countries. For further information, please visit the Ascensia Diabetes Care website at: About PHC Holdings Corporation PHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia Holdings Ltd., LSI Medience Corporation, Mediford Corporation, and Wemex. Together, these companies develop, manufacture, sell and service precision technology across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group's consolidated net sales in FY2024 were JPY 361.6 billion with global distribution of products and services in more than 125 countries. i Diabetes impacts the mental well-being of 3 in 4 people with the condition - International Diabetes Federation ii Diabetes Facts and Figures | International Diabetes Federation View source version on Contacts For media enquiries, please contact:Lorraine Chandler: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
23-07-2025
- Business
- Globe and Mail
Diabetes Clinical Trial Pipeline Experiences Rapid Expansion as Over 200+ Leading Companies Advance Novel Therapies
DelveInsight's, ' Diabetes Pipeline Insight 2025 ' report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in the Diabetes pipeline landscape. It covers the Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetes therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Diabetes Pipeline. Dive into DelveInsight's comprehensive report today! @ Diabetes Pipeline Outlook Key Takeaways from the Diabetes Pipeline Report In June 2025, Eli Lilly and Company announced a study is to assess the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India. The study will last about 33 weeks for each participant, including screening (1 week), Lead-in period (4 weeks), treatment period (26 weeks) and follow up period (2 weeks). DelveInsight's Diabetes pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Diabetes treatment. The leading Diabetes Companies such as vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc. and others. Promising Diabetes Therapies such as Aspirin, DA-2811, Forxiga, TG103, and others. Stay ahead with the most recent pipeline outlook for Diabetes. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Diabetes Treatment Drugs Diabetes Emerging Drugs Profile Cadisegliatin: vTv Therapeutics Cadisegliatin, also known as TTP399, is an innovative oral medication developed by vTv Therapeutics, designed as a liver-selective glucokinase activator. It aims to serve as an adjunctive therapy to insulin for individuals with type 1 diabetes (T1D). This drug has been recognized for its potential to improve glycemic control by enhancing hepatic glucose uptake and glycogen storage independently of insulin, addressing a critical need in diabetes management. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Diabetes. LY-3209590: Eli Lilly and Company Insulin efsitora alfa (LY3209590) is a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. Efsitora is in phase III development for adults with type 1 and 2 diabetes. CT-388: Roche CT-388 is a once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D). CT-388 was designed to have potent activity on both the GLP-1 and GIP receptors but with minimal to no ß-arrestin recruitment on either receptor. This biased signaling significantly minimizes receptor internalization and consequent desensitization, which is expected to lead to prolonged pharmacological activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Type 2 Diabetes Mellitus. HU6: Rivus Pharmaceuticals HU6 is an investigational, first-in-class oral therapy developed by Rivus Pharmaceuticals. It belongs to a new drug class called Controlled Metabolic Accelerators (CMAs), which are designed to selectively increase fat metabolism, leading to fat loss while preserving muscle mass. HU6 works by subtly increasing resting metabolism, specifically by activating a process called mitochondrial uncoupling. This process increases the oxidation of sugars and fats without reducing ATP (energy) production, resulting in the selective reduction of accumulated fat throughout the body. Currently, the drug is in the Phase II stage of development to treat Diabetes. XW014: Sciwind Biosciences XW014 is an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Sciwind Biosciences for the treatment of obesity and Diabetes (T2D). XW014 functions as a GLP-1 receptor agonist, which means it mimics the action of the GLP-1 hormone that is released after meals. This hormone plays a key role in regulating glucose metabolism by stimulating insulin secretion, inhibiting glucagon release, and promoting satiety. As an oral small molecule, XW014 offers advantages over traditional peptide-based GLP-1 therapies, such as ease of administration and the potential for combination therapies with other oral medications. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diabetes. K-833: Kallyope Inc. K-833 is an investigational oral small-molecule developed by Kallyope Inc., designed as a nutrient receptor agonist for the treatment of obesity and type 2 diabetes. K-833, often studied in combination with Kallyope's other candidate K-757, targets G-protein coupled receptors (specifically GPR119), which are involved in the release of hormones that suppress appetite and regulate glucose. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diabetes. The Diabetes Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Diabetes with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetes Treatment. Diabetes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetes market Explore groundbreaking therapies and clinical trials in the Diabetes Pipeline. Access DelveInsight's detailed report now! @ New Diabetes Drugs Diabetes Companies vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc. and others. The Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Diabetes Products have been categorized under various Molecule types such as, Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Diabetes Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Diabetes Market Drivers and Barriers Scope of the Diabetes Pipeline Report Coverage- Global Diabetes Companies- vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc. and others. Diabetes Therapies- Aspirin, DA-2811, Forxiga, TG103, and others. Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Diabetes Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Diabetes Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Diabetes: Overview Pipeline Therapeutics Therapeutic Assessment Diabetes– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Cadisegliatin: vTv Therapeutics Drug profiles in the detailed report….. Mid-Stage Products (Phase II) CPL207280: Celon Pharma Drug profiles in the detailed report….. Early Stage Products (Phase I) KN056: Suzhou Alphamab Co., Ltd. Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Diabetes Key Companies Diabetes Key Products Diabetes- Unmet Needs Diabetes- Market Drivers and Barriers Diabetes- Future Perspectives and Conclusion Diabetes Analyst Views Diabetes Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
